Drug Profile
Research programme: soluble epoxide hydrolase inhibitors - Arete Therapeutics
Alternative Names: AR 9273Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Arete Therapeutics
- Class
- Mechanism of Action Epoxide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension; Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hypertension in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA (PO)
- 17 May 2008 Pharmacodynamics data from a preclinical trial in a model of diet-induced obesity presented at the 23rd Annual Scientific Meeting of the American Society of Hypertension (ASH-2008)